学院简介     深圳大学高等研究院是深圳大学新成立的一个包含本科与研究生培养、侧重跨学科教学与研究的校内综合办学单位。作为深圳大学内部探索全面改革创新的学术特区,高等研究院与香港和海外著名高校合作,借鉴国外研究型大学通行的管理模式,引进具有一流视野的资深教授和发展潜力的青年教师,营造与国际接轨的学术氛围和培养环境,开展卓越的教学、研究和管理工作。 ······
新闻动态

高等研究院系列学术讲座之六十五

作者:admin | 发布时间:2017-04-10 | 浏览次数:2921
下一篇文章:

Translational Research in Chronic Lymphocytic Leukemia (CLL) Therapeutics

Dr. Jian YU

Moores Cancer Center, University of California, San Diego


About the Speaker

Dr. Yu was engaged in developing therapeutic strategies against leukemia, and published 4 papers as the first author in prestigious journals such as PNAS, J Clin Invest and Leukemia. As a lead researcher, Dr. Yu was involved in generating a first-in-class humanized mAb, cirmtuzumab, which is being evaluated in a phase I clinical trials for the treatment of Chronic Lymphocytic Leukemia patients.


Talk Information

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) was considered as a novel therapeutic target for CLL, which is an onco-embryonic antigen that is exclusively expressed on CLL cells, but not on normal postpartum tissues. My study focused on investigation of the mechanism of ROR1 signaling and development of monoclonal antibodies (mAbs) against ROR1 for the treatment of CLL patients. Cirmtuzumab could inhibit Wnt5a-induced RhoA and Rac1 activation, and impair the capacity of ROR1 to enhance migration and proliferation of leukemia cells in vitro and in vivo, providing rationale for the ongoing clinical evaluation of cirmtuzumab in CLL patients or other ROR1-dependent malignancies. Also, we demonstrated that cirmtuzumab and ibrutinib may have synergistic activity in the treatment of patients with CLL, providing the rationale for clinical trials using cirmtuzumab in combination with ibrutinib, or another inhibitor of BTK, such as acalabrutinib, for treatment of patients with CLL or other B-cell malignancies dependent on non-canonical Wnt5a/ROR1 signaling.

时间:2017年4月11号上午9:30-10:30

地点:办公楼628会议室(原620-12会议室)

All are welcome!